Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 419

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 419
---
,163 | ) |     |     249.6 | %  |
| Income tax                              |     |                  — |   |     |          — |   |     |          — |   |     |         — |    |
| Net loss                                |     |         (4,516,095 | ) |     | (1,291,932 | ) |     | (3,224,163 | ) |     |     249.6 | %  |
| Total other comprehensive income/(loss) |     |              1,569 |   |     |     42,308 |   |     |    (40,739 | ) |     |     (96.3 | )% |
| Total comprehensive loss for the year   |     |         (4,514,526 | ) |     | (1,249,624 | ) |     | (3,264,902 | ) |     |     261.3 | %  |
| Basic and diluted loss per share        |     |              (0.15 | ) |     |      (0.04 | ) |     |      (0.11 | ) |     |    (275.0 | )% |

____________ Notes: n.m. — not meaningful. Revenues Revenues decreased by $60,569, or 3.2%, from $1,879,939 for the year ended June 30, 2023, to $1,819,370 for the year ended June 30, 2024. Revenues from the Heritas Diagnostics segment decreased by $122,105, or 6.7%, from $1,824,664 for the year ended June 30, 2023, to $1,702,559, for the year ended June 30, 2024. This decline is attributable to a combination of volume and price effects: • volume effect: approximately 95.6% of the decline ($116,731) is due to a 6.4% reduction in testing volumes across key areas such as rare diseases, prenatal, and microbiome testing. Reduced customer demand, heightened competition, and evolving market conditions led to fewer tests performed; and • price effect: the remaining 4.4% of the decline ($5,374) is due to a 0.3% decrease in average pricing, which is quoted in U.S. dollars, driven by increased pricing pressures and competitive dynamics in the diagnostics market. In